Healthcare / Drug Manufacturers - Specialty & GenericSaudi
$60.25
+0.45 (+0.76%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 24% · confianza 25%
FCF escenarios
weak_data · normalized FCF $54.1M · quality 66.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
53/100
C
Piotroski
7/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
12/100
SEC 0%
Sin guardar todavía.
Market Cap
$2.1B
P/E
20.2x
↓EV/EBITDA
16.7x
↑ROE
23.3%
↑Gross Margin
62.3%
↑Debt/Equity
0.15
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2023–2025 · 2 años de histórico normalizado
Revenue CAGR
+16.6%
FCF CAGR
-6.3%
FCF margin
11.8%
FCF / Net income
0.56x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $460.5M · net income $97.0M · FCF $54.1M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | $460.5M | $460.5M | $394.0M | $338.4M |
| Net Income | $97.0M | $97.0M | $79.8M | $65.8M |
| EBITDA | $128.4M | $128.4M | $106.9M | $90.2M |
| EPS | 2.77 | 2.77 | 2.28 | 1.88 |
| Gross Margin | 62.3% | 62.3% | 61.8% | 60.3% |
| Operating Margin | 23.7% | 23.7% | 23.1% | 23.6% |
| Net Margin | 21.1% | 21.1% | 20.3% | 19.5% |
| Balance Sheet | ||||
| Debt/Equity | 0.15 | 0.15 | 0.17 | 0.20 |
| Current Ratio | 2.85 | 2.85 | — | — |
| Cash Flow | ||||
| Free Cash Flow | $54.1M | $54.1M | $12.1M | $61.7M |
| Returns | ||||
| ROE | 23.3% | 23.3% | 21.7% | 21.5% |
| Valuation | ||||
| P/E | 20.22 | 20.22 | 30.33 | — |
| EV/EBITDA | 16.65 | 16.65 | 23.02 | — |
| P/B | 5.07 | 5.07 | 6.57 | — |
| Growth & Yield | ||||
| Revenue Growth | 16.9% | 16.9% | 16.4% | — |
| EPS Growth | 21.6% | 21.6% | 21.2% | — |
| Dividend Yield | 2.3% | 2.3% | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
24.5%
EPS terminal req.
$5.35
Spread vs growth
-2.9%
5Y implied EPS CAGR
18.5%
EPS terminal req.
$6.47
Spread vs growth
3.1%
10Y implied EPS CAGR
14.2%
EPS terminal req.
$10.42
Spread vs growth
7.4%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-12.9%
Start / end P/E
30.8x → 21.5x
EPS bridge
2.28 → 2.77
Residual
-6.5%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.